ASCO 2020 Archives -

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the

Gilead trumpets data with newly-bought magrolimab in blood cancers

https://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi

AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer

https://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO)

ASCO 2020 virtual annual meeting – day 3

https://pharmaphorum.com/oncology/asco-2020-virtual-meeting-day-3/

With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now

ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers

https://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/

Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough

Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trials

https://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO)

ASCO 2020 virtual annual meeting – day 2

https://pharmaphorum.com/oncology/asco-2020-virtual-meeting-day-2/

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO)

ASCO 2020 virtual annual meeting – day 1

https://pharmaphorum.com/oncology/asco-2020-virtual-meeting-day-1/

ASCO 2020